Latest News

Category: Events

See all

Investor Education Webinar: The Future of Prostate Imaging: What do physicians want?

Events, News,

Telix invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate...

Read more

Presentation to J.P. Morgan Healthcare Conference

ASX, Events,

Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference...

Read more

ZIRDOSE-CP Study of TLX250-CDx published in EJNMMI Research: Confirms Favorable Safety and Tolerability Profile in Chinese patients

ASX, Events,

Telix today announces that final results from the ZIRDOSE-CP Phase 1 study of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma (ccRCC) have been published...

Read more

Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference

ASX, Events,

Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA...

Read more

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Events, News,

Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco,...

Read more

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

Events, News,

Telix today announces thirteen abstract presentations featuring the Company’s ongoing theranostic development, medical technologies (MedTech), and research and innovation (R&I) programs at the 37th Annual Congress of the European Association...

Read more

Telix Announces Abstract Presentations at BNMS Annual Spring Meeting 

Events, News,

Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week....

Read more

First Patient Dosed in Austrian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent 

Events, News,

Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...

Read more

Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591 

Events, News,

Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May...

Read more

First Patient Dosed in Special Access Scheme in Australia for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent 

Events, News,

Telix today announces that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®) positron emission tomography (PET) imaging in clear cell...

Read more